Celgene Corporation Contingent Value Rights
CELGZ
CELGZ was delisted on the 29th of November, 2019.
19 hedge funds and large institutions have $1.02M invested in Celgene Corporation Contingent Value Rights in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
35% less capital invested
Capital invested by funds: $1.57M → $1.02M (-$550K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.08K |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
+$2.44K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$517 |
| 5 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$287 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$15K |
| 2 |
MSTVIM
Messner & Smith Theme Value Investment Management
San Diego,
California
|
-$10.3K |
| 3 |
First Manhattan
New York
|
-$3.45K |
| 4 |
FA
FCG Advisors
Chatham,
New Jersey
|
-$309 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$8 |
CELGZ Hedge Fund Activity: Q4 2017 in Review
19 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q4 2017, worth a combined $1.02M — down 35% from $1.57M a quarter earlier.
Fund positioning in CELGZ was balanced in Q4 2017: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $34.1K. The largest seller was Deutsche Bank, exiting entirely with an estimated $15K sold.
- 19 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $1.02M of Celgene Corporation Contingent Value Rights stock for Q4 2017, down 35% quarter-over-quarter.
- 1 fund opened new Celgene Corporation Contingent Value Rights positions in Q4 2017 and 1 closed out, a net change of 0 holders.
- The largest Celgene Corporation Contingent Value Rights buyer in Q4 2017 was Susquehanna International Group, an estimated $34.1K added.
- The largest Celgene Corporation Contingent Value Rights seller in Q4 2017 was Deutsche Bank, an estimated $15K sold.
Based on aggregated 13F filings for Q4 2017.